Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Eli Lilly's Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea
The FDA approved Eli Lilly's tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used with a reduced-calorie diet and exercise. Zepbound, a once-weekly injectable, reduces body weight, which improves OSA, and is the first drug therapy for this condition. It showed significant reduction in breathing disruptions per hour and weight loss in clinical trials, posing a competitive challenge to CPAP device makers.
BioWire Weekly - 025 - by David Kingsley, PhD
AI-discovered drugs show high Phase I success rates, mirrored life poses risks, AI physicians show promise but need integration, and FDA cracks down on unapproved GLP-1 drugs.
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
U.S. large-cap biopharma stocks underperformed the broader market for two consecutive years due to political uncertainty and sector rotation. JP Morgan analysts remain positive on key players like Eli Lilly, Bristol-Myers Squibb, Merck & Co., Regeneron Pharmaceuticals, Gilead Sciences, and AbbVie Inc. Animal health stocks, including Zoetis Inc and IDEXX Laboratories, are also projected to rebound in 2025. Specialty pharmaceuticals showed early signs of stabilization in 2024.
Wegovy weight loss drug gets price cut in Israel—but only for lower doses
Starting Jan 1, Wegovy's lower doses in Israel drop from NIS 723 to NIS 579/month, but higher doses remain at NIS 1,300. Mounjaro, more effective, stays at NIS 1,800, highlighting healthcare access disparity. Both meds mimic hormones for weight loss, with Wegovy also aiding diabetes, heart health, and sleep apnea treatment.
FDA approves Zepbound for obstructive sleep apnea
FDA approves Zepbound for treating moderate-to-severe obstructive sleep apnea and obesity. Trials show Zepbound reduces breathing disruptions and aids weight loss, but side effects include digestive issues and potential thyroid tumors.
Outlook 2025: India's CDSCO gives nod to sell 19 new drugs in 2024
In 2024, India's CDSCO approved 19 new drugs, including next-gen therapies for chronic diseases by global majors. Eli Lilly's Mounjaro for diabetes/obesity, Orchid Pharma's Enmetazobactam for resistant bacteria, Cipla's plazomicin for UTIs, Sun Pharma's Etifoxine for anxiety, Dr Reddy's Elobixibat for constipation, and Zydus/Lupin's Vonoprazan for stomach ulcers were notable. New cancer drugs like Eli Lilly's Retevmo and Zydus's nelarabine were also approved.
FDA Approves Weight-Loss Drug to Treat Obstructive Sleep Apnea
The FDA approved Zepbound, the first prescription drug for obstructive sleep apnea, for people with obesity and moderate to severe sleep apnea. Studies showed improvement in symptoms with Zepbound compared to a placebo. The drug's compound, tirzepatide, also aids weight loss and is used in diabetes treatment. The approval may increase demand for obesity medications and influence insurance coverage.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
FDA approves Eli Lilly's Zepbound for moderate-to-severe sleep apnea and obesity, marking the first medication for obstructive sleep apnea. Zepbound, a GLP-1 drug, should be used with a reduced-calorie diet and increased physical activity. Studies show it reduces breathing pauses and promotes weight loss, though side effects include nausea and stomach discomfort. Concerns over GLP-1 medication prices persist.
New weight-loss treatment becomes first FDA-approved drug for sleep apnea
The FDA approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, the first drug to directly treat the disorder. The approval is for moderate to severe obstructive sleep apnea in adults with obesity, potentially expanding the market and strengthening Lilly’s case with insurers. Zepbound, a GLP-1 agonist, also reduces food cravings and slows stomach emptying, with trial data showing it eased breathing difficulties and lowered sleep apnea biomarkers.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea
Eli Lilly's weight loss drug Zepbound approved by FDA for treating obesity and moderate-to-severe obstructive sleep apnea (OSA), expanding its use and potentially insurance coverage in the U.S. Zepbound, first approved for obesity, is now cleared for OSA, a common sleep-related breathing disorder affecting 80 million in the U.S., with 85% undiagnosed. Eli Lilly expects to launch the drug for OSA early next year, with clinical trials showing Zepbound reduced OSA severity and resolved the condition in nearly half of patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath